Robert M. Califf

Adjunct Professor of Medicine
Donald F. Fortin, M.D. Distinguished Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Publications

Fleurence, Rachael L., Lesley H. Curtis, Robert M. Califf, Richard Platt, Joe V. Selby, and Jeffrey S. Brown. “Launching PCORnet, a national patient-centered clinical research network.” J Am Med Inform Assoc 21, no. 4 (July 2014): 578–82. https://doi.org/10.1136/amiajnl-2014-002747.

PMID
24821743
Full Text

Holman, Rury R., Harald Sourij, and Robert M. Califf. “Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.” Lancet 383, no. 9933 (June 7, 2014): 2008–17. https://doi.org/10.1016/S0140-6736(14)60794-7.

PMID
24910232
Full Text

Vemulapalli, Sreekanth, Jamy Ard, George L. Bakris, Deepak L. Bhatt, Alan S. Brown, William C. Cushman, Keith C. Ferdinand, et al. “Proceedings from Duke resistant hypertension think tank.” American Heart Journal 167, no. 6 (June 2014): 775-88.e1. https://doi.org/10.1016/j.ahj.2014.02.008.

PMID
24890525
Full Text

Hill, Kevin D., Karen Chiswell, Robert M. Califf, Gail Pearson, and Jennifer S. Li. “Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov.” Am Heart J 167, no. 6 (June 2014): 921-9.e2. https://doi.org/10.1016/j.ahj.2014.02.002.

PMID
24890544
Full Text

Wong, Ka Sing Lawrence, Dai Yi Hu, Abraham Oomman, Ru-San Tan, Manesh R. Patel, Daniel E. Singer, Günter Breithardt, et al. “Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.” Stroke 45, no. 6 (June 2014): 1739–47. https://doi.org/10.1161/STROKEAHA.113.002968.

PMID
24763930
Full Text

Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan L. Halperin, Günter Breithardt, Rod Passman, Graeme J. Hankey, et al. “Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.” Heart Rhythm 11, no. 6 (June 2014): 925–32. https://doi.org/10.1016/j.hrthm.2014.03.006.

PMID
24833235
Full Text

Sherwood, Matthew W., James D. Douketis, Manesh R. Patel, Jonathan P. Piccini, Anne S. Hellkamp, Yuliya Lokhnygina, Alex C. Spyropoulos, et al. “Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).” Circulation 129, no. 18 (May 6, 2014): 1850–59. https://doi.org/10.1161/CIRCULATIONAHA.113.005754.

PMID
24552831
Full Text

Inrig, Jula K., Robert M. Califf, Asba Tasneem, Radha K. Vegunta, Christopher Molina, John W. Stanifer, Karen Chiswell, and Uptal D. Patel. “The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov.” Am J Kidney Dis 63, no. 5 (May 2014): 771–80. https://doi.org/10.1053/j.ajkd.2013.10.043.

PMID
24315119
Full Text

Kalogeropoulos, Andreas P., WH Wilson Tang, Amy Hsu, G Michael Felker, Adrian F. Hernandez, Richard W. Troughton, Adriaan A. Voors, et al. “High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial.” J Card Fail 20, no. 5 (May 2014): 319–26. https://doi.org/10.1016/j.cardfail.2014.02.002.

PMID
24530944
Full Text

Pages